These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 33157041)

  • 1. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.
    Pateliya B; Burade V; Goswami S
    Eur J Pharmacol; 2021 Jan; 891():173725. PubMed ID: 33157041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: an experimental study.
    Pateliya B; Burade V; Goswami S
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Sep; 394(9):1949-1961. PubMed ID: 34125254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cordycepin Enhances the Therapeutic Efficacy of Doxorubicin in Treating Triple-Negative Breast Cancer.
    Huang H; Li X; Wu W; Liu C; Shao Y; Wu X; Fu J
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
    Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
    Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein.
    Zhang FY; Du GJ; Zhang L; Zhang CL; Lu WL; Liang W
    Pharm Res; 2009 Apr; 26(4):914-25. PubMed ID: 19067124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
    Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
    Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
    Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
    Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.
    Himmel LE; Lustberg MB; DeVries AC; Poi M; Chen CS; Kulp SK
    Exp Toxicol Pathol; 2016 Oct; 68(9):505-515. PubMed ID: 27555377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
    Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
    Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
    Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
    Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
    Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
    Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
    Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
    Wokoun U; Hellriegel M; Emons G; Gründker C
    Oncol Rep; 2017 Apr; 37(4):2418-2424. PubMed ID: 28350075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.